This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Precision Medicine in Severe Asthma: The Importance of Phenotypes and Endotypes in Patient Evaluation

Precision Medicine in Severe Asthma: The Importance of Phenotypes and Endotypes in Patient Evaluation

Format

Webcast

Time to Complete

30 minutes

Released

September 13, 2019

Expires

September 13, 2020
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM
0.50 / ABIM MOC Point

An important note about ABIM MOC Part II points
Successful completion of this CME activity enables eligible participants to earn up to 0.50 ABIM-Part II Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. To claim MOC points, follow these easy steps:

Step 1: Complete all 3 questions under the "ABIM Part 2 Credit Questions" section, located at the bottom of the course evaluation form. This includes 1) attesting that our partner may submit your credits to ABIM, 2) attesting that you are ABIM board certified, 3) providing your ABIM #, and 4) providing your date of birth (MM/DD).

Step 2: Our partner, The University of Cincinnati, will send your MOC points to your ABIM account within 6-8 weeks.

Accredited Provider



Provided by University of Cincinnati

Commercial Supporter

Supported by educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals and Novartis Pharmaceutical Corporation

Program Description

Severe asthma affects only 3-6% of the overall population of asthmatics, but accounts for nearly half of the annual expenditures among asthma patients. Advances in the understanding of the pathophysiology of severe asthma have led to the identification of specific asthma endotypes and phenotypes that may be used to better tailor therapy in the future. This activity will explore the value of determining patient endotypes and phenotypes and review biomarker testing that can help clinicians appropriately classify severe asthma patients.

Intended Audience

Pulmonologists, allergists, primary care physicians (PCPs), NPs, PAs and other healthcare providers who manage patients with severe asthma

Educational Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Identify the characteristics of uncontrolled, difficult-to-treat, and severe asthma.
  • Describe how the pathophysiology of asthma produces distinct disease phenotypes/endotypes for characterization of severe asthma.
  • Summarize clinical, laboratory, and other diagnostic findings that are consistent with each phenotype/endotype of severe asthma to improve treatment selection and asthma control.

Faculty

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Division of Pulmonary, Critical Care
& Sleep Medicine
National Jewish Health
Denver, CO

Dr. Wechsler discloses the following:
Grants/Research Support: AstraZeneca, Teva, GlaxoSmithKline, Sanofi Genzyme Regeneron
Consultant: AstraZeneca, Teva, GlaxoSmithKline, Sanofi Genzyme Regeneron, Genetech/Novartis

Emily DiMango, MD
Professor of Medicine
Director, John Edsall-John Wood Asthma Center
Columbia University Medical Center
New York, New York

Dr. DiMango discloses the following:
Advisory Board: AstraZeneca

Accredited Provider Disclosures

Susan P. Tyler, MEd, CMP, CHCP, CME Director, University of Cincinnati, has no conflicts of interest to disclose.
Bruce C. Gebhardt, MD, CME Reviewer-Compliance, University of Cincinnati, has no conflicts of interest to disclose.
Heather Muskopf, Program Manager, Continuing Medical Education, University of Cincinnati, has no conflicts of interest to disclose.

Publishing Staff Disclosures

The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The University of Cincinnati designates this enduring material activity for a maximum of 0.50 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification (from ABIM):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Unlabeled Use

The credit providers require all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

©2019 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the University of Cincinnati, or Sanofi Genzyme and Regeneron Pharmaceuticals and Novartis Pharmaceutical Corporation. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Instructions

To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the University of Cincinnati Continuing Medical Education Department at uccme@uc.edu or call 513-558-7277.
Add to Queue